More on ALGS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+24.8% Growth)
- Ratings (8.0 Score)

Upcoming Events

- Earnings (7/30/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Aligos Therapeutics Inc. (NQ:ALGS)
Delayed: 4.06 -0.02 (0.49%)
Prev. Close $4.08  
Open$4.09 
52 Wk High$ 
52 Wk Low$ 
Day High$4.27 
Day Low$3.98 
P/E N/A  
EPS$ 
Volume182,420 


Jul 14, 2026 07:04 AM H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)
Jul 13, 2026 08:00 AM Aligos completes enrollment in phase 2 HBV drug study
Jul 13, 2026 08:00 AM Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Jul 8, 2026 06:44 AM H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)
Jul 6, 2026 04:05 PM Aligos receives $25M upfront from China license deal for HBV drug
Jul 6, 2026 04:05 PM Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Jun 29, 2026 04:38 PM Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Preston Heather
Jun 29, 2026 04:38 PM Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Chavez Margarita
Jun 29, 2026 04:37 PM Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Martell Bridget A
Jun 29, 2026 04:37 PM Form 4 Aligos Therapeutics, For: Jun 25 Filed by: Scopa James Paul
View All Articles

Entities mentioned with ALGS

View All Entities